Within the tumor microenvironment, stromal and immunosuppressive barriers such as CAF- and MDSC-derived TGF-β and IL-10 secretion, ECM fibrosis, hypoxia, and metabolic competition continue to impair CAR-T trafficking, persistence, and function. This evidence concerns the gene TGFB1 and neoplasm.